Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
Status:
Completed
Trial end date:
2017-04-25
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if it is safe and feasible to transplant
changed cord blood for patients with leukemia or lymphoma. Researchers also want to learn if
this can help to control the disease.
The cord blood will be changed to make use of sugar that is found in small amounts in blood
cells. It plays a role in signaling where in the body the transplanted cells should go to.
Adding more sugars to the cord blood cells in the laboratory is designed to help the cord
blood cells find their way faster to the bone marrow. This may help your blood counts to
recover faster. This process is called fucosylation.
Anti-thymocyte globulin (ATG) is a protein that removes immune cells that cause damage to the
body.
Clofarabine is designed to interfere with the growth and development of cancer cells.
Fludarabine is designed to interfere with the DNA (genetic material) of cancer cells, which
may cause the cancer cells to die. This chemotherapy is also designed to block your body's
ability to reject the donor's bone marrow cells.
Melphalan and busulfan are designed to bind to the DNA of cells, which may cause cancer cells
to die.
Mycophenolate mofetil (MMF) and tacrolimus are designed to block the donor cells from growing
and spreading in a way that could cause graft versus host disease (GVHD -- a condition in
which transplanted tissue attacks the recipient's body). This may help to prevent GVHD.
Rituximab is designed to attach to cancer cells, which may cause them to die.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
American Stem Cell, Inc. National Cancer Institute (NCI)